The unpatentable cure

In a trial across eleven Indian hospitals, surgeons gave 796 women with early breast cancer a few injections of 0.5% lidocaine — the same numbing agent in every dentist's drawer — into the tissue around the tumor, seven to ten minutes before cutting. The other 804 women got surgery alone. Five years on, 90.1% of the lidocaine group were alive versus 86.4% of the controls: a 29% drop in the relative death rate, with no drug-related side effects, from a generic that costs pennies and already sits in every operating room.

No company stands to profit from a generic nobody can patent — so the confirmatory trials never got funded.

The result was published in a leading oncology journal in 2023, and then mostly sat there. No company stands to profit from a decades-old anesthetic nobody can patent, so no one funded the confirmatory trials that turn a striking number into a guideline. The nonprofit Every Cure, run by physician David Fajgenbaum, took up the case — listing it among results with strong evidence but no commercial champion, and getting the first known US patient dosed in late 2024.

The mechanism is still unexplained: lab studies suggest lidocaine blocks the sodium channels cancer cells use to spread, but the concentrations that work in a dish are far higher than what's safe in a patient's blood. The trialists estimate wider adoption could save over 100,000 lives a year. The harder lesson is that a finding this cheap and this large can go unused for years simply because the economics that fund medicine had no reason to carry it forward.